4 stories mentioning BOM:532331Updated 38d ago
Every FINWIRES story that references BOM:532331, newest first.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has an average rating of buy and mean price target of 3,268.38 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) recorded a rise in its consolidated net profit to 2.67 billion Indian rupees in the fiscal fourth quarter ended March 31 from 2.25 billion rupees a year ago.Earnings per share climbed to 21.34 rupees from 18 rupees a year earlier, according to a Tuesday filing by the pharmaceutical company.Revenue from operations in fiscal Q4 also increased to 14.2 billion rupees from 11.7 billion rupees a year earlier, the filing said.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has received five observations from the US FDA concluded an inspection at our manufacturing facility at Paithan in Maharashtra, India, according to a filing to the Indian stock exchanges.The regulator inspected the facility from April 13 to 21 and closed with the issuance of Form-483 with five observations.The company said it will respond to the U.S. FDA within the stipulated timeline.The company's shares were down nearly 1% in recent trade.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has an average rating of buy and mean price target of 3,238.25 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
